YN360162 Zamicastat 1080028-80-3

Zamicastat (BIA 5-1058) is adopamine β-hydroxylase (DBH)inhibitor and can cross the blood-brain barrier (BBB) to cause central as well as peripheral effects. Zamicastat is also a concentration-dependent dualP-gp and BCRPi...

YN290086 TC-S 7005 1082739-92-1

TC-S 7005 is aPolo-like kinases (Plks)inhibitor with IC50s of 4nM, 24nM and 214nM for Plk2, Plk3, and Plk1, respectively.

YN330667 HNGF6A 1093111-54-6

HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits ofROSproduction during oxidative stress. HNGF...

YN360629 (3R,5R)-Rosuvastatin 1094100-06-7

(3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoAreductase inhibitor with an IC50 of 11nM. Rosuvastatin potently blockshuman ether-a-go-go related gene (hERG)current wit...

YN5340016 ITD-1 1099644-42-4

ITD-1 is a potent TGF-β inhibitor. It does not block the kinase activity of either type I (TGFBR1) or type II (TGFBR2) TGFβ receptors but potently blocks phosphorylation of the effector SMAD2/3 proteins i...

YN321048 Aprocitentan 1103522-45-7

Aprocitentan (ACT-132577) is the major and pharmacologically active metabolite of Macitentan. Aprocitentan is dualETA/ETBantagonist with IC50s of 3.4nM and 987nM, and pA2valus of 6.7 and 5.5, respectively.

YN370052 TM5275 sodium 1103926-82-4

TM 5275 sodium is an orally bioavailable plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 6.95 μM..

YN450084 KY02111 1118807-13-8

KY02111 promotes differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, may act downstream of APC and GSK3β.

YN321388 Doxazosin D8 1126848-44-9

Doxazosin D8 (UK 33274 D8) is a deuterium labeled Doxazosin (UK 33274). Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1 adrenergic receptors.

YN450047 ROCK inhibitor-2 1127308-52-4

ROCK inhibitor-2 is a selective dualROCK1 and ROCK2inhibitor with IC50s of 17nM and 2nM, respectively.

YN360628 Rosuvastatin D3 1133429-16-9

Rosuvastatin D3 (ZD 4522 D3) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hE...

YN320247 SR59230A hydrochloride 1135278-41-9

SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetratingβ3-adrenergic receptorantagonist with IC50s of 40, 408, and 648nM for β3, β1, and β2 receptors, respectively.

YN372562 GSK2256294A 1142090-23-0

GSK2256294A is a potent, reversible, tight binding inhibitor of isolated recombinant human sEH (soluble epoxide hydrolase) (IC50 = 27 pM; t1/2 = 121 min) and displays potent inhibition against the rat (IC50 = 61 pM) and muri...

YN321044 Clopidogrel thiolactone 1147350-75-1

Clopidogrel thiolactone is a P2Y12 receptor inhibitor, is a potent antiplatelet agent Clopidogrel thiolactone is the metabolic intermediate resulting from the first oxidative activation of clopidogrel.

YN371070 Molidustat 1154028-82-6

Molidustat (BAY 85-3934) is a potent hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with IC50 of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD, respectively. Phase 2.

YN371017 PHPS1 sodium 1177131-02-0

PHPS1 sodium is a potent and selectiveShp2inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.

YN420071 Metformin D6 hydrochloride 1185166-01-1

Metformin D6 hydrochloride is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits themitochondrial respiratory chainin the liver, leading to activation ofAMPK, enhancing insulin sensitivity for type 2 diabe...

YN321608 Cinnarizine D8 1185242-27-6

Cinnarizine D8 is a deuterium labeled Cinnarizine. Cinnarizine is an antihistamine and a calcium channel blocker.

YN480335 TMN355 1186372-20-2

TMN355 (Compound 3i) is a potent inhibitor of cyclophilin A (CypA) with IC50 of 1.52 nM and reduces foam cell formation and cytokine secretion. TMN355 is used for the treatment of atherosclerosis.

YN371390 Evacetrapib 1186486-62-3

Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3.